Cargando…
Characterization of in-vivo human metabolites of the oral nucleoside anti-COVID-19 drug VV116 using UHPLC-Orbitrap-MS
VV116 is an oral nucleoside anti-COVID-19 drug undergoing clinical trials in China. We aimed to characterize its metabolites in plasma, urine, and feces of healthy Chinese male subjects after a single oral administration of 400 mg VV116, by using UHPLC-UV-Orbitrap-MS. After oral administration, VV11...
Autores principales: | Zhou, Ainan, Wang, Zhen, Diao, Xingxing, Zhong, Dafang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008097/ https://www.ncbi.nlm.nih.gov/pubmed/36924632 http://dx.doi.org/10.1016/j.jpba.2023.115340 |
Ejemplares similares
-
In Vivo Metabolite Profiling of DMU-212 in Apc(Min/+) Mice Using UHPLC-Q/Orbitrap/LTQ MS
por: Li, Jing, et al.
Publicado: (2023) -
Identification of the metabolites of isochlorogenic acid A in rats by UHPLC-Q-Exactive Orbitrap MS
por: Gong, Kaiyan, et al.
Publicado: (2020) -
Pharmacokinetics and Metabolism Research of Shenkang Injection in Rats Based on UHPLC-MS/MS and UHPLC-Q-Orbitrap HRMS
por: Jiang, Xiaofang, et al.
Publicado: (2020) -
Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects
por: Qian, Hong-jie, et al.
Publicado: (2022) -
Metabolites Identification and Mechanism Prediction of Neobavaisoflavone In Vitro and In Vivo of Rats through UHPLC-Q-Exactive Plus Orbitrap MS Integrated Network Pharmacology
por: Li, Linlin, et al.
Publicado: (2022)